Regulation Of Ribosomal RNA Gene Chromatin During Malignant Transformation.
Funder
National Health and Medical Research Council
Funding Amount
$882,486.00
Summary
The overarching goal of this proposal is to determine the molecular basis for tumour cell dependence on activated ribosomal RNA gene repeats (rDNA). Our working model posits that rDNA repeats become activated through changes in rDNA chromatin structure that include increased binding of the RNA Polymerase I transcription factor UBF.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE110100121
Funder
Australian Research Council
Funding Amount
$360,000.00
Summary
Three-dimensional super-resolution nanophotonic fabrication facility. This stimulated emission depletion microscopy nanophotonic fabrication facility will be the first nanophotonic fabrication facility that is able to achieve optical resolution far beyond the diffraction limit, which will facilitate breakthroughs in cutting-edge nanotechnology research areas.
Policy Modelling for Ageing in Emerging Economies: The Case of Indonesia. This project, in collaboration with the World Bank and the Indonesian Planning Authority, will support major social and economic policy development in a rapidly ageing region. It will break new ground by developing a cutting-edge economic policy model reflecting salient features of ageing in emerging economies, taking into account the wider implications for education, employment, formalisation, growth, and retirement. It w ....Policy Modelling for Ageing in Emerging Economies: The Case of Indonesia. This project, in collaboration with the World Bank and the Indonesian Planning Authority, will support major social and economic policy development in a rapidly ageing region. It will break new ground by developing a cutting-edge economic policy model reflecting salient features of ageing in emerging economies, taking into account the wider implications for education, employment, formalisation, growth, and retirement. It will bring the armoury of policy analysis instruments available to these countries up to the standard now enjoyed by the developed world. Indonesia, on the brink of major pension reform, will be used as a test bed. Data sets will be developed to allow the model structure to be applied to other emerging economies in Asia. Read moreRead less
We have discovered a single tumour factor which causes cancer cachexia, a wasting condition that is one of the worst complications of malignancy, for which there is no current effective treatment. We have developed antibodies which effectively block this condition in preclinical models and have produced human/humanised version of this. This application is to characterise these human antibodies to allow us proceed to clinical trials.
Alpha-particles linked to recombinant antibodies targeting tumour cells have potential to effectively treat tumours while minimising normal tissue side effects. We will explore a novel alpha-particle therapy approach to solid tumours, by delivering 225Ac directly into tumour cells, or into cells that support the tumour (microenvironment). This approach will hopefully result in development of a new approach to treatment of cancers that are resistant to conventional therapies.
Melanotransferrin: A “Missing Link” And A Novel Pharmacological Target For Treatment
Funder
National Health and Medical Research Council
Funding Amount
$613,848.00
Summary
Despite >30 years of research, the precise function of the protein, melanotransferrin (MTf), is unknown. However, we have breakthrough evidence that MTf stimulates WNT signalling as a major driver in cancer progression. We will investigate this hypothesis, which will underpin new cancer therapies. Indeed, we designed a new class of drugs that target the WNT pathway via up-regulating the WNT inhibitor, NDRG1. This drug (DpC) inhibits MTf expression to block tumour cell growth and metastasis.
Humanisation And Pre-clinical Validation Of A Therapeutic Anti-cancer Antibody
Funder
National Health and Medical Research Council
Funding Amount
$699,136.00
Summary
This grant will develop a novel antibody against a protease expressed on cancer cells. Preclinical studies, and antibody humanisation, will be performed. This project will also provide vital information on optimal therapeutic approaches with the antibody that can be ultimately taken into human trials.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100006
Funder
Australian Research Council
Funding Amount
$600,000.00
Summary
An adaptable and dedicated linear accelerator for medical radiation research. Leading radiation scientists developing innovative methods and devices for treating cancer patients will collaborate in future research using this highly adaptable linear accelerator for medical radiation research. Innovations in tumour targeting, better patient safety, new medical devices and improved cancer outcomes are expected.
ADAM Metalloprotease Inhibition For Treatment Of Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$770,925.00
Summary
Colorectal cancer (CRC) causes over 4000 deaths/year, typically from developing drug resistance and spreading to other organs (metastasis). These processes involve tumour cells called cancer stem cells (CSCs), which rely on specific cell surface proteins for survival and function. We are developing antibodies against one of these type of proteins, to test in mouse models of CRC. These already show promise in targeting CSCs and inhibiting drug-resistance and metastasis in mice.